Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc., trading under the ticker BLUW, is a specialty pharmaceutical company that entered the public markets through a business combination with Blue Water Acquisition Corp, a healthcare-focused SPAC that completed its initial public offering in 2020 with Blue Water Acquisition Sponsor LLC serving as sponsor. The company is focused on hormone-related therapies, including an FDA-approved oral testosterone replacement treatment, placing it squarely within the life sciences and specialty pharmaceuticals sector. The 8-K filing dated August 27, 2021, under accession number 0001213900-21-045339, reflects a material event disclosure submitted in connection with the de-SPAC transaction. Sign up for full data on SpacDesk to access complete filing histories, sponsor profiles, and deal analytics across the SPAC universe.